1 results match your criteria: "Moffitt Cancer Center Tampa Florida 33612 USA andrii.monastyrskyi@moffitt.org.[Affiliation]"
RSC Chem Biol
October 2024
Department of Drug Discovery, Moffitt Cancer Center Tampa Florida 33612 USA
The CDK12 inhibitor SR-4835 promotes the proteasomal degradation of cyclin K, contingent on the presence of CDK12 and the CUL4-RBX1-DDB1 E3 ligase complex. The inhibitor displays molecular glue activity, which correlates with its enhanced ability to inhibit cell growth. This effect is achieved by facilitating the formation of a ternary complex that requires the small molecule SR-4835, CDK12, and the adaptor protein DDB1, leading to the subsequent ubiquitination and degradation of cyclin K.
View Article and Find Full Text PDF